PCM
CRBU icon

Prelude Capital Management’s Caribou Biosciences CRBU Stock Holding History

Prelude Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,166
Closed -$17.5K – 1056
2025
Q1 		$17.5K Sell
19,166
-15,810
-45% -$20.5K ﹤0.01% 1134
2024
Q4 		$55.6K Buy
34,976
+6,966
+25% +$14K ﹤0.01% 1144
2024
Q3 		$54.9K Buy
28,010
+1,600
+6% +$3.28K ﹤0.01% 1210
2024
Q2 		$43.3K Buy
26,410
+6,800
+35% +$21.7K ﹤0.01% 1154
2024
Q1 		$101K Buy
19,610
+3,476
+22% +$21.4K 0.01% 1198
2023
Q4 		$92.4K Buy
+16,134
New +$79.8K 0.01% 1034
2023
Q3 		– Sell
-23,900
Closed -$102K – 1167
2023
Q2 		$102K Buy
+23,900
New +$107K 0.01% 930

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's CRBU Position: Q2 2025 in Review

Prelude Capital Management sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 19,166 shares — an estimated $17.5K sold.

Prelude Capital Management first reported a position in CRBU in Q2 2023 and held it in 7 quarters. The position peaked at $102K in Q2 2023. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • Prelude Capital Management reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 19,166 Caribou Biosciences shares in Q2 2025, an estimated $17.5K.
  • Prelude Capital Management first reported a position in Caribou Biosciences in Q2 2023 and held it in 7 quarters.
  • Prelude Capital Management's Caribou Biosciences position peaked at $102K in Q2 2023.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.